• Dexamethasone (DHAP): Precision Engineering in NF-κB Pathway

  2026-04-30

  Discover how Dexamethasone, a potent glucocorticoid anti-inflammatory, enables advanced modulation of NF-κB signaling and stem cell differentiation. This article uniquely bridges recent bioactive compound insights with practical guidance for neuroinflammation and cellular pathway studies.

• PR-619: Deubiquitylating Enzymes Inhibitor for Pathway Resea

  2026-04-29

  PR-619 is a reversible, broad-spectrum deubiquitylating enzymes inhibitor optimized for dissecting ubiquitination pathways in live cell systems. Its cell-permeability and broad DUB specificity make it a cornerstone for autophagy, cancer, and neurodegeneration workflows, with robust troubleshooting advantages over proteasome inhibitors.

• Nicotine and Chronic Kidney Disease Progression: Mechanistic

  2026-04-29

  This review elucidates the mechanistic role of nicotine in the progression of chronic kidney disease (CKD), highlighting non-neuronal nicotinic acetylcholine receptor signaling, oxidative stress, and pro-fibrotic pathways. The findings provide a foundation for targeted research on interrupting these pathways to mitigate CKD risk in smokers.

• O-GlcNAcylation Drives Wnt-Induced Bone Formation via Glycol

  2026-04-28

  This study uncovers a central role for O-GlcNAcylation in mediating the effects of Wnt signaling on osteoblast differentiation and bone formation. By linking metabolic reprogramming to post-translational modification, the work provides new mechanistic insights relevant to osteoporosis and bone repair.

• Rack1-Mediated Ferroptosis Shapes Hindgut Development in ARM

  2026-04-28

  This study provides spatial transcriptomic evidence that Rack1 downregulation induces ferroptosis via the P38-MAPK/Nqo1/Gpx4 axis, affecting hindgut development in a rat model of anorectal malformations (ARM). The findings clarify a mechanistic link between ferroptotic cell death and congenital digestive tract anomalies, offering new avenues for targeted research into oxidative lipid damage inhibition.

• AG-490 (Tyrphostin B42): Precision JAK2/EGFR Inhibition in C

  2026-04-27

  AG-490 (Tyrphostin B42) enables high-fidelity modulation of JAK-STAT and MAPK signaling, empowering researchers to dissect immune and oncogenic pathways in complex cellular contexts. This guide translates cutting-edge evidence and practical expertise into actionable workflows for cancer and immunopathology bench scientists.

• S-Adenosylhomocysteine: Mechanistic Benchmarks & Research Us

  2026-04-27

  S-Adenosylhomocysteine (SAH) is a central methylation cycle regulator and metabolic intermediate. It enables precise modulation of methyltransferase activity and is essential for understanding homocysteine metabolism and SAM/SAH ratio dynamics. APExBIO’s SAH (B6123) provides standardized, research-grade material for accurate metabolic and epigenetic assays.

• Mubritinib (TAK 165) Disrupts OXPHOS in KSHV-Driven Lymphoma

  2026-04-26

  This study identifies Mubritinib (TAK 165) as a potent inhibitor of primary effusion lymphoma (PEL) driven by Kaposi’s sarcoma-associated herpesvirus (KSHV), acting through disruption of mitochondrial oxidative phosphorylation. The research delivers mechanistic clarity on Mubritinib’s selectivity for KSHV+ cancer cells, establishing a precedent for repurposing mitochondrial complex I inhibitors in virus-driven lymphomas.

• Pifithrin-α: Applied p53 Inhibitor Workflows for Apoptosis &

  2026-04-25

  Pifithrin-α (PFTα) empowers precise control of p53-dependent apoptosis and ferroptosis, enabling breakthroughs in neurotoxicity and cancer therapy side effect mitigation. This guide translates recent reference findings into actionable, optimized protocols and troubleshooting strategies for advanced cell-based assays.

• Nicotine Signaling Accelerates CKD Progression in Smokers

  2026-04-24

  Jain and Jaimes provide a comprehensive review of how nicotine, acting via non-neuronal nicotinic acetylcholine receptors, exacerbates chronic kidney disease (CKD) progression in smokers. Their synthesis of clinical and experimental evidence highlights nicotine's role in oxidative stress and fibrosis, suggesting new molecular targets for mitigating smoking-induced renal injury.

• Thrombin B Chain: Redefining Translational Coagulation Model

  2026-04-24

  This thought-leadership article explores the mechanistic and translational frontiers of thrombin, a trypsin-like serine protease, focusing on the APExBIO Coagulation Factor II (Thrombin) B Chain Fragment. By integrating current mechanistic research, experimental best practices, and strategic guidance, the article empowers translational researchers to elevate the fidelity of their vascular and fibrin matrix models. The discussion draws on recent literature, including the unexpected pro-angiogenic effects of bestatin in fibrin matrices, and offers a critical appraisal of the competitive landscape. The article concludes with a visionary outlook on the role of ultra-pure thrombin products in next-generation translational workflows.

• SPRTN’s Dual Ubiquitin Binding: Fast Proteolysis of DNA-Prot

  2026-04-23

  This study uncovers how SPRTN protease harnesses a dual ubiquitin binding mode to achieve targeted and rapid degradation of polyubiquitinated DNA-protein crosslinks (DPCs). The findings clarify a critical mechanism for genome stability and inform advanced protein analysis workflows.

• GI 254023X: Advanced Workflow Strategies for ADAM10 Inhibiti

  2026-04-23

  GI 254023X stands out as a highly selective ADAM10 inhibitor, empowering researchers to dissect cell signaling, apoptosis, and vascular integrity with unprecedented precision. This guide delivers actionable protocols, troubleshooting know-how, and a translational edge for leveraging GI 254023X in preclinical models.

• Monoclonal Antibody Inhibits CD16 Shedding and Boosts ADCC

  2026-04-22

  This study introduces a novel monoclonal antibody (F9H4) that selectively prevents CD16a and CD16b shedding without broadly inhibiting ADAM17, thereby enhancing antibody-dependent cellular cytotoxicity (ADCC) in cancer models. The findings offer a substrate-specific approach to improving the efficacy of Fc-mediated immunotherapies while minimizing off-target effects.

• Dexamethasone (DHAP): Integrative Control of Inflammation an

  2026-04-22

  Explore the advanced applications of dexamethasone as a glucocorticoid anti-inflammatory in research, uniquely focusing on its dual modulation of signaling and cell fate. This article offers a protocol-driven, evidence-based perspective for optimizing experimental design.

453 records 20/31 page Previous Next First page 上5页 1617181920 下5页 Last page